Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 4/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857344 | 0.86 | CYP3A4 (0.36) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4302121 | 0.81 | MAPK14 (0.37) | MAPK14 | |
| SCHEMBL3839427 | 0.81 | KDM4E (0.37) | — | |
| SCHEMBL4303007 | 0.79 | PTGER4 (0.39) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3839835 | 0.78 | HDAC1 (0.43) | DAO | |
| SCHEMBL2798863 | 0.76 | KMT2A (0.39) | PER2CRY1CRY2 | |
| SCHEMBL2795647 | 0.76 | ALDH1A1 (0.47) | PER2CRY1CRY2 | |
| SCHEMBL3222281 | 0.75 | KDM4E (0.47) | — | |
| SCHEMBL2512106 | 0.73 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL4302268 | 0.73 | PRPS1 (0.33) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | MAPK13 4178/4885MAPK12 2963/4885MAPK11 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.